{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thoracic+Tumor&page=32", "query": { "condition": "Thoracic Tumor", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 5201, "total_pages": 521, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thoracic+Tumor&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Thoracic+Tumor&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T08:02:52.979Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00346801", "title": "CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "CPT-11", "type": "DRUG" }, { "name": "Concurrent Thoracic Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 20, "start_date": "2003-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-10-22", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00346801" }, { "nct_id": "NCT05363605", "title": "A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Head and Neck Squamous Cell Carcinoma", "Bladder Carcinoma", "Susceptible FGFR3 Genetic Alterations", "FGFR3", "FGFR3 Overexpression", "FGFR3 Receptor", "FGFR3 Protein Overexpression", "Ovarian Cancer", "Colorectal Cancer", "Breast Cancer", "Liver Cancer", "Lung Cancer", "Gastric Cancer" ], "interventions": [ { "name": "[225Ac]-FPI-1966", "type": "DRUG" }, { "name": "[111In]-FPI-1967", "type": "DRUG" }, { "name": "vofatamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fusion Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-04-20", "completion_date": "2023-09-08", "has_results": false, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 4, "location_summary": "Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363605" }, { "nct_id": "NCT01579929", "title": "Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "LDE225, Etoposide and Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2012-04", "completion_date": "2017-08-11", "has_results": false, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" }, { "city": "Sleepy Hollow", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01579929" }, { "nct_id": "NCT06540495", "title": "Virtual Personalized Exercise Program for Lung Cancer Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Salaso Virtual Exercise Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-06-03", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 1, "location_summary": "New Hyde Park, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06540495" }, { "nct_id": "NCT04410796", "title": "Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 571, "start_date": "2020-05-28", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 18, "location_summary": "Sacramento, California • San Francisco, California • Tampa, Florida + 13 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04410796" }, { "nct_id": "NCT00100256", "title": "Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Small Cell", "Neoplasm Recurrence, Local" ], "interventions": [ { "name": "Rhenium (Re 188 P2045, BAY86-5284)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andarix Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 60, "start_date": "2004-01", "completion_date": "2025-04-20", "has_results": false, "last_update_posted_date": "2022-11-07", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Baltimore, Maryland", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100256" }, { "nct_id": "NCT05153239", "title": "Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Small Cell Lung Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Lurbinectedin", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaMar", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 705, "start_date": "2022-07-22", "completion_date": "2026-04-10", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 15, "location_summary": "Chandler, Arizona • Hot Springs, Arkansas • Fort Myers, Florida + 12 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05153239" }, { "nct_id": "NCT00918281", "title": "Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "High Grade Gliomas", "Lung Cancer", "Head and Neck Cancer", "Sarcoma", "Renal Cell Carcinoma", "Breast Cancer" ], "interventions": [ { "name": "Fluciclatide Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2009-06", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00918281" }, { "nct_id": "NCT03939481", "title": "Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Lung Non-Small Cell Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Stage I Lung Cancer AJCC v8", "Stage I Ovarian Cancer AJCC v8", "Stage IA Ovarian Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage IB Ovarian Cancer AJCC v8", "Stage IC Ovarian Cancer AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage II Ovarian Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIA Ovarian Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage IIB Ovarian Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Functional Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1336, "start_date": "2019-05-14", "completion_date": "2027-02-01", "has_results": true, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 166, "location_summary": "Antioch, California • Dublin, California • Fremont, California + 132 more", "locations": [ { "city": "Antioch", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03939481" }, { "nct_id": "NCT00112294", "title": "Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Paclitaxel (Taxane)", "type": "DRUG" }, { "name": "Docetaxel (Taxane)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 755, "start_date": "2004-12", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2015-12-24", "last_synced_at": "2026-10-29T08:02:52.979Z", "location_count": 124, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112294" } ] }